`
`mm
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 241
`
`DEFOREST MCDUFF, Ph.D.
`
`for the declarations in the IPR cases, correct?
`
`A.
`
`Q.
`
`Yes, that's correct.
`
`All right.
`
`Now,
`
`there was a
`
`question or some questions at the start of the
`
`deposition about the contents of your
`
`respective declarations, and so if you have
`
`those with you,
`
`they were Exhibit 1055 which
`
`was
`
`your declaration in the 1622 case and
`
`Exhibit 1055 which was your exhibit in the 1621
`
`case .
`
`Now,
`
`I believe there was some
`
`testimony about some omissions in the 1621 case
`
`from your declaration.
`
`Can you tell us what
`
`the omissions were?
`
`A.
`
`Yes. As submitted and in the
`
`version in front of me,
`
`there was a chart on
`
`page 9 that appears to have been omitted for a
`
`printing issue and the attachments from page 26
`
`to page 45 which are present in Exhibit 1055 in
`
`the 1622 case are not present in my declaration
`
`in Exhibit 1055 in the 1621 case. Yet the
`
`attachments are identical to those in the 1622
`
`case .
`
`
`
`So the 1622 case at the
`Okay.
`Q.
`
`
`800-642-1099
`
`A Veritext Company
`
`ww.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 241 of 297
`
`
`
`DEFOREST MCDUFF, Ph.D.
`
`end of paragraph 15 has a chart in it; is that
`
`Page 242
`
`right?
`
`A.
`
`Q.
`
`the 1621 case?
`
`Yes.
`
`And that chart is omitted in
`
`A.
`
`Q.
`
`In the declaration there, yes.
`
`But it should have been the
`
`identical chart is that correct?
`
`A.
`
`Yes.
`
`MR. DELAFIELD: Objection.
`
`BY MR. MATHAS:
`
`Q.
`
`All right. What chart should
`
`have been there?
`
`MR. DELAFIELD:
`
`Same objection.
`
`BY THE WITNESS:
`
`A.
`
`The same chart that is in the
`
`1622 declaration as well as in the underlying
`
`materials cited in footnote 6 in the 1621
`
`declaration.
`
`BY MR. MATHAS:
`
`Q.
`
`All right. And the exhibits
`
`that were omitted in the 1621 case, how, if at
`
`all, were they different from the exhibits
`
`
`
`submitted in the 1622 case?
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 242 of 297
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`Page 243
`
`DEFOREST MCDUFF, Ph.D.
`
`A.
`
`They were identical.
`
`MR. MATHAS: All right.
`
`Can we
`
`mark this as Exhibit 3, please —- or 4 for the
`
`record, please.
`
`MR. DELAFIELD:
`
`I am going to
`
`object to this exhibit.
`
`MR. MATHAS:
`
`Fine,
`
`I am making a
`
`record.
`
`(WHEREUPON, a certain document
`
`was marked McDuff Deposition
`
`Exhibit No. 4, for
`
`identification, as of 4/6/18.)
`
`BY MR. MATHAS:
`
`Q.
`
`Dr. McDuff,
`
`the court reporter
`
`has
`
`handed you what's been marked for
`
`identification purposes as McDuff Exhibit 4
`
`which I will represent to you is a corrected
`
`version of Exhibit 1055 that was sent to
`
`counsel for the patent owner last evening.
`
`This has not been filed in the IPR proceeding
`
`as of today.
`
`Would you turn with me,
`
`please,
`
`to page 9 the end of paragraph 15.
`
`
`
`Does paragraph 15 in Exhibit 4 that I just
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 243 of 297
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`Page 244
`
`DEFOREST MCDUFF, Ph.D.
`
`handed you correctly show the chart that was
`
`omitted from your original Exhibit 1055 and
`
`1621?
`
`A.
`
`Q.
`
`Yes.
`
`And if you will turn with me
`
`to page 26 through 45 of this Exhibit 4 that I
`
`have handed you, do pages 26 through 45 of
`
`Exhibit 4 correctly reflect the omitted exhibit
`
`from the original Exhibit 1055?
`
`A.
`
`Q.
`
`Yes.
`
`Are you aware of any other
`
`differences between the document I have handed
`
`you as Exhibit 4 and the document that was
`
`filed as Exhibit 1055 in IPR 1621?
`
`A.
`
`No,
`
`I am not.
`
`MR. MATHAS:
`
`I have no further
`
`questions.
`
`FURTHER EXAMINATION
`
`BY MR. DELAFIELD:
`
`Q.
`
`I have a couple of questions.
`
`So this new declaration that
`
`we received yesterday, do you see at the bottom
`
`it says page 1 of 25?
`
`
`
`I do.
`A.
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 244 of 297
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`boron-
`
`03-40301
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 245
`
`DEFOREST MCDUFF, Ph.D.
`
`Q.
`
`A.
`
`But there's 45 pages, correct?
`
`Yes,
`
`there are 45 pages in the
`
`declaration including the declaration and the
`
`attachments.
`
`Q.
`
`So the page numbering is off
`
`for the first 25 pages with respect to how many
`
`total pages, correct?
`
`A.
`
`Yes,
`
`I suppose that could say
`
`page 1 of 45, and it would say 45 consistently
`
`throughout as it does in the attachments.
`
`Q.
`
`A.
`
`Did you -—
`
`Either way I think it
`
`represents the full declaration.
`
`Q.
`
`Did you yourself prepare this
`
`replacement declaration?
`
`A.
`
`I did not do so personally.
`
`I
`
`did so through discussion and assistance from
`
`counsel.
`
`Q.
`
`And you said you first noticed
`
`the missing exhibits and graph yesterday as
`
`well?
`
`A.
`
`Yes.
`
`MR. DELAFIELD: Okay.
`
`I have no
`
`
`
`further questions.
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page2450f297
`
`
`
`Page 246
`
`DEFOREST MCDUFF, Ph.D.
`
`MR. MATHAS:
`
`One follow up.
`
`FURTHER EXAMINATION
`
`BY MR. MATHAS:
`
`Q.
`
`Dr. McDuff, do the -- does the
`
`additional information in Exhibit 4 or the
`
`absence of the information in Exhibit 4 change
`
`your opinions with respect to the ‘240 patent
`
`in case 1621?
`
`A.
`
`No,
`
`they are all the same
`
`either way regardless of whether it's the full
`
`document with all of the attachments and chart
`
`or the abridged document that omits those.
`
`MR. MATHAS:
`
`Thank you.
`
`I have no
`
`further questions.
`
`FURTHER EXAMINATION
`
`BY MR. DELAFIELD:
`
`Q.
`
`One question.
`
`You were asked
`
`if the information in Exhibit 4 or the absence
`
`of information of Exhibit 4 would change your
`
`opinions with respect to the '240 patent,
`
`correct?
`
`A.
`
`Q.
`
`More or less.
`
`So if your declaration did not
`
`
`
`then you
`have any of the exhibits or the chart,
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 246 of 297
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`Page 247
`
`DEFOREST MCDUFF, Ph.D.
`
`couldn't rely on those in your declaration or
`
`cite them, correct?
`
`MR. MATHAS: Object to the form.
`
`BY THE WITNESS:
`
`A.
`
`I don't agree with that.
`
`The
`
`most relevant charts from my attachments are in
`
`both copies of the declaration.
`
`The charts
`
`themselves are in line in paragraphs 24 and
`
`25
`
`- sorry -— 23 and 24, and the attachments
`
`simply provide the supporting calculations
`
`underlying those charts, but the fundamental
`
`opinions are the same.
`
`BY MR. DELAFIELD:
`
`Q.
`
`And so without the
`
`attachments,
`
`there would be no supporting
`
`calculations for the '240 declaration, correct?
`
`MR. MATHAS: Object
`
`to the form.
`
`BY THE WITNESS:
`
`A.
`
`There would be no details
`
`underlying how the calculations were performed.
`
`However,
`
`they are described in the declaration
`
`itself.
`
`MR. DELAFIELD: Okay.
`
`I have no
`
`
`
`further questions.
`
`
`800-642-1099
`
`A Veritext Company
`
`ww.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 247 of 297
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`Page 248
`
`DEFOREST MCDUFF, Ph.D.
`
`MR. MATHAS:
`
`Thank you, Dr. McDuff.
`
`THE VIDEOGRAPHER:
`
`The time is now
`
`4:18 p.m. This is the end of media 4. This
`
`concludes this deposition. We are off the
`
`record.
`
`(WHEREUPON,
`
`the deposition was
`
`concluded at 4:18 p.m.)
`
`
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-O1622
`
`Page 248 of 297
`
`
`
`Page 249
`
`STATE OF ______________ )
`
`COUNTY OF
`
`:ss
`
`)
`
`I
`
`I, DEFOREST MCDUFF,
`
`the witness
`
`herein, having read the foregoing
`
`testimony of the pages of this deposition,
`
`do hereby certify it to be a true and
`
`correct transcript, subject to the
`
`corrections, if any,
`
`shown on the attached
`
`page.
`
`DEFOREST MCDUFF
`
`Sworn and subscribed to before me,
`
`this ________ day of __________ , 2018.
`
`Notary Public
`
`
`
`OD-JO‘U'I-waI-l
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 249 of 297
`
`
`
`OD-dthU'l-waI-l
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`Page 250
`
`CERTIFICATE
`
`OF
`
`CERTIFIED SHORTHAND REPORTER
`
`I, ANDREA L. KIM, a State of Illinois
`
`Licensed Certified Shorthand Reporter, License
`
`number 84-3722, do hereby certify:
`
`commencement of the examination of the
`
`That previous to the
`
`aforesaid witness,
`
`the witness was duly sworn
`
`or affirmed to testify the whole truth
`
`concerning the matters herein;
`
`That the foregoing deposition
`
`transcript was reported stenographically by me,
`
`was
`
`thereafter reduced to typewriting under my
`
`personal direction and constitutes a true and
`
`accurate record of the testimony given and the
`
`proceedings had at the aforesaid deposition;
`
`That the said deposition was
`
`taken before me at the time and place
`
`specified:
`
`That I am not a relative or
`
`employee or attorney or counsel for any of the
`
`
`
`parties herein, nor a relative or employee of
`
`
`800-642-1099
`
`A Veritext Company
`
`ww.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 250 of 297
`
`
`
`Pag
`
`e 251
`
`such attorney or counsel for any of the parties
`
`hereto, nor am I interested directly or
`
`indirectly in the outcome of this action.
`
`IN WITNESS WHEREOF,
`
`I do
`
`hereunto set my hand and affix my seal of
`
`office at Chicago, Illinois,
`
`this 9th day of
`
`April, 2013.
`
`awn 0%? Kan;
`
`ANDREA L. KIM, CSR
`
`License No. 84-3722.
`
`
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`800-642-1099
`
`A Veritext Company
`
`www.veritext.com
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES V. UNITED THERAPEUTICS, |PR2017-O1622
`Page 251 of 297
`
`
`
`INSTRUCTIONS TO WITNESS
`
`Page 252
`
`Please read your deposition over carefully
`
`and make any necessary corrections. You should state
`
`the reason in the appropriate space on the errata
`
`sheet for any corrections that are made.
`
`After doing so, please sign the errata sheet
`
`and date it.
`
`You are signing same subject to the changes
`
`you have noted on the errata sheet, which will be
`
`attached to your deposition.
`
`It is imperative that you return the original
`
`errata sheet to the deposing attorney within thirty
`
`(30) days of receipt of the deposition transcript by
`
`you. If you fail to do so,
`
`the deposition transcript
`
`may be deemed to be accurate and may be used in court.
`
`
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`800-642-1099
`
`A Veritext Company
`
`wwwxeritextcom
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-O1622
`
`Page 252 of 297
`
`
`
`Page 253
`
`E R R A T A
`
`I wish to make the following changes,
`
`for the following reasons:
`
`PAGE LINE
`
`___
`
`___ CHANGE:
`
`REASON:
`
`CHANGE:
`
`REASON:
`
`REASON:
`
`REASON:
`
`REASON:
`
`REAS ON :
`
`CHANGE:
`
`CHANGE:
`
`CHANGE:
`
`CHANGE:
`
`WITNESS ' SIGNATURE
`
`DATE
`
`
`
`{AMI-l
`
`mm
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`1'7
`
`18
`
`19
`
`20
`
`21
`
`22
`
`23
`
`24
`
`25
`
`
`
`800-642-1099
`
`A Veritext Company
`
`ww.veritext.com
`
`David Feidman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, |PR2017-01622
`
`Page 253 of 297
`
`
`
`1055 23:8,14 27:12
`
`36:3 37:12,23
`39:3 71:2 83:20
`
`242:2 243:24,25
`152
`149:21
`
`16 77:19 81:17
`
`112:11125z25
`
`82:16 83:6 87:8
`
`129211241:8,10
`
`241:20,22 243:19
`
`98:22112:11,l2
`116:7 156:21
`
`244:3,10,15
`1057 205:19
`
`229:11,12
`
`10:52 64:4,7
`
`11
`
`113:5,24138z2
`162:9 175:2
`
`158:13,23162:10
`172:24
`
`1621 37:25 241:10
`
`241:13,22 242:6
`
`242:19,23 244:4
`244:15 246:9
`
`187:17 235:11
`
`1622 37:24 39:14
`
`1113
`
`161:14,17
`
`40:8 83:20 110:25
`
`172:13,l7,25
`
`241 :9,21 ,23,25
`
`[& - 2006]
`
`‘& 2:4,11,19 5:16
`5:19,22
`
`0
`
`01622 23:16 67:11
`
`033 228:3
`
`075 89:17 206:4
`
`210:2],25 211:12
`
`211:17,19,21
`212:4 213:7 214:3
`
`214:12,22,25
`
`215:4,14,20 216:3
`216:9 217:16
`
`218:15 219:6,17
`
`219:25 220:20,24
`
`221:3,11,13,20
`
`222:4 223:6,14
`225:21227:3
`
`232:22
`
`1
`
` &
`
`Page 1
`
`1994 162:2,16
`
`163:11,25164:7
`174:23
`
`1999 212:16,17,20
`232:23
`
`1:26 129:3,5
`
`2
`
`2 4:16 64:9 128:23
`
`163:10172:13
`
`231:8,12
`2.5 152:15153:14
`
`153:24 154:7,21
`160:18
`
`2.515 36:25152:25
`
`20 20:3,5 73:24
`
`74:3,18 75:2
`
`83:23 86:19,20
`88:5 95:3 99:14
`
`99:18,19118:16
`
`118:17119:9,16
`
`160:4,4163:15
`176:11184:15
`
`1140
`
`103:15,16,21
`
`103:22,24 104:5
`1160
`103:21 104:4
`
`104:19,21 120:7
`123:19
`' 1162 64:18 65:11
`
`242:18,25
`1621 116:8
`
`17 158:13163:7,8
`172:18
`
`18 43:9 67:2 68:24
`
`70:19 73:24 74:17
`
`78:3 81:22 83:16
`
`1
`
`4: 14 39:4 49:21
`
`50:3 51:12 64:4
`
`66:6,1167:10,18
`74:25 77:10 82:12
`
`
`
`83:23,25 85:9,11
`86:19 87:21 88:2
`
`88:11 98:14 99:5
`
`100:8
`
`19 66:10 67:18
`
`70:19 83:23 89:15
`
`190 4:14
`
`19705
`
`162:13
`
`1980 211:2 217:17
`
`218:19
`
`1980s
`
`162:14
`
`1990 162:2,15
`
`163:1],25164:7
`174:23 175:14
`
`1990s
`
`161:16
`
`162:14211:6
`
`227:13
`
`1991 220:16
`
`67:18149:16
`
`l90:l4,18 244:24
`245:10
`
`1.111 64:25 65:17
`
`1.114 64:2065:13
`
`1.132 66:14
`
`1.3 159:10,l9
`10 114:10117:15
`
`118:13 119:9
`
`129:17 191:20
`
`196:23
`
`100
`
`119:10
`
`1001 42:2 45:6
`
`1018 205:14,14
`228:6
`
`1019 205:2,4206:5
`1025 205:8219:22
`
`110:24111:13,19
`1163 64:23 65:15
`
`77:9,11,20 80:3
`81:16 82:16 111:6
`
`111:25
`
`119 72:10
`
`11:03 64:7,9
`12
`159:25 160:3
`
`161:22 235:25
`
`236:9,21
`121 239:10
`
`12:35 128:23
`
`129:3
`
`13 83:20132:25
`
`236:8,22,25 237:8
`
`18:6 40:3,8
`15
`41:3 77:25 81:21
`
`83:14 85:8160:4
`
`800-642-1099
`
`A Veritext Company
`
`ww.veritext.com
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-O1622
`
`Page 254 of 297
`
`227:13,14
`
`
`
`200,000 146:19
`
`147:4,8,11,20
`149:14152:14
`
`153:8,11
`2000 162:5 175:9
`
`176:22211:6
`
`20007 2:21
`
`2000s
`
`162:14
`
`175:10,15
`2001
`177:10217:15
`
`219:15
`
`
`
`2002 161:6163:19
`
`176:19217:13,15
`218:20
`
`2004 120:4,8
`
`2006 211:8,11,12
`
`211:14212:5,5,8
`
`212:14213:4,5,6
`
`
`
`[2007 - 60606]
`Page 2
`
`
`2007 235:1]
`
`22125 223:5
`
`237221
`
`2009 26:9,16 27:15
`
`73:7 ”6220,25
`
`120:2,11 152:24
`160:19 183:13
`
`224220
`
`224:16,19 225220
`
`226210 227:2,6,18
`228:2 232:25
`
`233:5
`
`23 74:25 77:9,11
`149220 151222
`
`116:9,21,22
`2010
`12022 17623
`
`152:10 161:3
`
`247:10
`
`224220 231 :25
`
`234 4:17
`
`2010s 224221
`
`24 43:9 45:16
`
`2013 27:212823
`
`142:6 151:24
`
`72:7
`
`152:7 158220
`
`2014 27:212823
`
`73:7
`
`2015 142:1]
`
`184221
`
`142:12,12
`2016
`152225160:19
`
`184221
`
`160:2 247:9,10
`240 4:6 36:18
`
`37:13,]8 39:17
`
`40:16 41:4,6
`45:19 47:22 48:9
`
`48:14 49:3,16
`
`50:9,18 51:24
`
`3
`
`3 421712925
`
`13822419126
`
`19321919423
`
`204:15 23422125
`236:8 243:4
`
`3.5
`
`15921]
`
`3.565
`
`158:24
`
`30 176211252214
`
`3000 2:20
`
`31
`
`90:3
`
`32 27:20
`
`325
`
`149210
`
`33
`
`146214
`
`333 226211
`
`34 27211,]9
`3S 12182259028
`
`99:14100223
`
`218:8
`
`36 99:15
`
`40 8:2
`
`439 72:11
`
`45
`
`152222 241220
`
`24427,8 245:2,3,10
`245210
`
`470 149221
`
`4800 1:18
`
`4:01 240:2,4
`
`4:10 240:4,6
`
`4:18 248:4,8
`
`5
`
`5 80:2137:8138:3
`
`141212
`
`5,153,222 205:9
`219:23
`
`50 7:25 8:1216:13
`
`507 23:17 3623,18
`
`41:5 44:4,7 45215
`45:23 47:2148:9
`
`48214 4923,17
`
`
`
`4 421,18 36:4 7123
`
`71215 73:2,6
`141222152221
`
`204220 243:4,12
`
`243:17,25 244:7,9
`
`244:14 246:6,7,l9
`246120 248:4
`
`4,306,075 20523
`476718 190:]5
`
`23129 234222
`
`243213
`
`
`
`37 6420,25 65:13
`65217 66:13 84:4
`
`87:21 90:9 99:15
`
`106:5,6
`38 36:2152:22
`
`3:03 204:15,18
`
`3:13 204:18,20
`
`4
`
`
`
`5029,17 51:24
`
`52225 5422,15
`
`55:1158:9,13
`
`59:14 64:21,25
`71:2 125225
`
`129212 210222
`
`21127,21212:18
`212125 213:9
`
`214:4 227:18
`
`540 45:21
`
`6
`
`6 4:5 5:740:14
`
`242219
`
`6,521,212 205:15
`228:6
`
`6,756,033 205221
`229211
`
`600 2220
`
`60606 2:6
`
`2017
`
`19:23 24:7
`
`25:16 34:4 39:6
`
`39:21 40:21
`
`142212184222
`
`2017-01621
`
`1:6
`
`18:25 23:15 39:4
`
`53:2 54:2,14
`
`55:10 58:9,12
`
`59:14 65:14,18
`
`2102212112722
`
`212:18,25 213:9
`214:4 227219
`
`45:6 65:1 1,15
`2017-01622 1:7
`
`2462821 247217
`243 4:18
`
`18:24 23 29 42:2
`
`244 4:7
`
`64:19,23
`2017-1062] 37:12
`
`246 428,9
`25 4:24 24:3 39:4
`
`2018 1:20 5:7 34:2
`
`39:16 244:24
`
`249221251210
`
`245:7 247:10
`
`21 24:6 39:20
`
`26 25:10 66:19
`
`83:23 87:21 89:18
`
`77:20 81 :16 84:4
`
`212 226:1] 228:2
`
`87:21 241:19
`
`228:1]
`
`22 66:9 6722 68:22
`
`244:7,8
`27 89:22 210:2
`
`217217
`
`28 89:24 210:24
`
`222 8921720427
`
`218:15 220:15,24
`
`800-642-1099
`
`David Feldman Worldwide
`
`A Veritext Company
`
`ww.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2017-O1622
`
`Page 255 of 297
`
`
`
`[6th - agree]
`Page 3
`
`
`‘ 6th 1:19
`
`7
`
`1:20 5:8 64:4
`. a.m.
`64:7,7,9
`
`acoustical 50:4
`51:12,15
`
`administering
`62:19 236:3
`
`_
`
`_
`
`:0 lfifillfilggl
`1199
`2:61:323239'11
`78746-5546 2:14
`
`.
`
`8
`8 41312 66118
`11932512633
`129212132324
`13428 135113
`136321 137314
`3,410,121 4117
`23532
`80 8112 201435
`
`ability 137:11
`
`7:
`
`127:13
`able
`$3433 221:14
`abridged 246:13
`absence 41:2
`246:7,19
`. abstract 194:8
`232:4 235:16
`academic 8:23
`178:9,ll,11
`acceptable 236:7
`accepting 178:2
`accepts
`179:11
`access 240:14,18
`240:24
`
`7219,12 157:8
`
`account
`
`127:5
`
`84-3722 1118 3122
`
`131:8 137:14
`
`250:8 251: 14
`
`140:3 152:9
`
`9
`'9 41:12 241:18
`
`189:11
`I accounting 189:21
`
`9,339,507 42:6
`9,358,240 45.?-
`9,550,716 231.13
`9,550.716..231
`4:16
`
`90 77:25 81:21
`
`83:14 85:8118:2
`
`119:3,13156:25
`900 2:12
`
`905 227:10
`
`9:35 5:8
`
`9:37 1:20
`
`9th 251:9
`
`a
`
`I a.d.
`
`1:20
`
`accumulated
`26.25
`accurate 23224
`25:15 37:18
`
`105:21162:12
`
`250:18252:16
`
`accurately 156:4
`accused 9:7
`
`achieve 127:13
`
`157:2,8
`achieved 13:17
`
`33:15 142:10
`
`187:16
`
`achieving 13:21
`117:18118:22
`
`acknowledges
`
`110:3,5
`
`
`
`action 107:3
`
`active
`
`1 7:
`
`138:18 139:13,14
`251:5 3 20
`220:12
`activities 208:21
`actual
`155:9 161:9
`162:4,9,20,22
`163:22164:6,15
`175:6,8186:17
`187:1],22
`adcirca 126:13
`137:4,8,15
`add 117:25 119:2
`addition 22:10
`83:24
`
`additional 8:3
`
`89:4121:17
`
`159:12 246:6
`
`address 84:24
`85:18 86:25 87:15
`
`100:9101:9
`addressed 44'10
`44218 84:21 15216
`addresses 43:14
`
`98:23 101:11
`
`178:12
`
`addressing 87:22
`124:2]
`
`129:18
`adempas
`130:9,23 132:16
`
`133:3,5
`administer 53:24
`
`55:9,24 56:10
`
`228:14 229:15,23
`administered
`
`61:2175:5101:19
`
`106:21
`
`
`
`administration
`
`5:
`
`55:16 105:24
`:28:1; 110:7
`advanced 28:17
`134:3,10
`120:18
`advantage
`120:23 121:24
`122:10
`advantages 81:4
`95:6 98:15 12025
`121:3,4
`adverse 80:6
`affect 7:20 55:20
`144:8,25 197:15
`affirmed 250:12
`
`affix 251:8
`
`aforesaid 250:1]
`
`250:19
`
`agent 236:15,23
`ago 38:11 162:10
`
`12:5 14:19
`agree
`33'4 3412144120
`44:12 4625,11,,14
`48:12 49:2 57:13
`
`58:22 60:2 68:4
`
`68:17 73:6,14
`75:9 76:16 83:9
`
`8524,23 86:6,14
`87:13 92:14 94:18
`
`98:6,12 99:3,13
`
`104:16,18105:10
`110:9111218
`
`112:8 119:16
`
`121:19122:25
`
`123:5 131:12
`
`133:15140:22
`
`141:10142:5
`
`
`
`800-642-1099
`
`A Veritext Company
`
`wwveritextcom
`
`David Feldrnan Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`
`Page 256 of 297
`
`
`
`Page 4
`[agree - area]
`
`analyses 48:4
`158:8
`
`analysis 10:99
`
`11:35 26:23 33:9
`
`34:4,5,5 42:14
`
`43:13,]4 44:16,20
`
`45:16,24 46:8
`47:9 48:10 71:10
`
`199:22 239220
`
`134:8 158214
`
`analyzes
`
`161:25
`
`analyzing 30:15
`140:4 160223
`
`236:22 241:18
`
`apples 35:18,18,21
`35221
`
`166210169:5,16
`193222
`
`applicability
`127:11
`
`andrea 1:16 3:21
`
`5:11250:6 251213
`
`19:19
`applicable
`34:5 114:3 176:4
`
`71:19,21,22 81:4
`
`annual
`
`142:25
`
`96:24,25 97:12
`101221 113225
`
`145:14149:20
`
`158223 161:4
`
`131:10139:22
`
`answer 6:25 7:9
`
`140:15 141:7
`
`142:2 143:24
`
`144:3,6 145224
`151215 152:9
`
`153217156213
`157216159:19
`
`19:9,14,14,18
`
`29:13 52:5 79:8,9
`100215137217
`
`153218 154:3
`
`181:12
`
`answered 87:17
`
`apportionment
`
`14921215025
`
`151:21154:13,19
`
`l64:5,13,25 165:4
`169:14180:10
`
`181:25186216
`
`187:9 189:17
`
`1902247 191215
`
`1922722 193:2]
`
`194:9,21 197:9
`201 :9 207224
`
`208:15,25 211:20
`
`212:3,4 213:14,22
`217:9 219:16
`
`222:12,22 223:13
`
`238:9,25 247:6
`
`agreement 75211
`
`178220
`agrees
`ahead 22:4
`
`allege 38:14
`alleged 49:12
`55:15 74:17 78:19
`
`application 101:5
`218:12
`
`applications 213:4
`applied 28:21
`applies 46:8,12
`186:22 224:4
`
`apply 30:4153219
`186:21200:18
`
`201:6
`
`10:7,10,24,25 11:2
`
`11:15,19
`
`appropriate 10:13
`
`128:12140:6,19
`140:23 141:4
`
`16124,7,8 166:16
`166224168:17
`
`94:20 97:3,19
`108:4 213:12
`
`169:2 173:23
`
`answers
`
`7216 9:5
`
`80:23 83:21 84:3
`
`17721317821
`
`19:1166:4155:16
`
`
`
`antagonist 138:13
`anticoagulants
`113:9
`
`anybody 212:22
`apologies 144:2]
`
`apologize 91:3
`
`apparently 218: 19
`
`appeal
`
`1:3
`
`appear 66:24 70:6
`72:6 77:15 79:22
`
`81:6 82:13 95:7
`
`106:3 175:12
`
`appeared 2:2,10
`appears 23:22
`24:2 40:3 42:8
`
`69:7 76:16 80:14
`
`82:10 104:24
`
`105:21116:19
`
`
`
`165:2 166214
`
`171:2 174:2 252:5
`
`appropriately
`48:10
`
`approval
`147:25
`
`120:8
`
`approved 80:9
`105:12 114:5
`
`116:4 120:4,10
`134:8138:4157:2
`
`157:8
`
`approximately 5:7
`7:2219:24 21:13
`
`147214149210
`
`1220 5:7
`april
`251210
`
`area 31:19 34:24
`
`118:8 119219
`
`109:3
`
`
`
`9812,14 99:22
`
`100:3,20,25
`238220
`
`alleviate
`
`134:20
`
`allow 158:17
`
`238216
`
`allows 29:811026
`
`223225
`
`alternative 56217
`
`57:11 70:23 72:19
`
`amendment 64:24
`
`65:16
`
`179:6 183:3 187:4
`
`191:17192:17,24
`193:5 197:25
`
`198:5,24 200:9
`
`201222 203:14,20
`207216214217
`
`225:14,15 230:18
`240:14
`
`analyze 43:12
`
`150:2,4 161:2
`170:10172:2
`
`184:10 189:25
`
`amount 158:5
`
`195:3 196:2
`
`183:18 222:7
`
`amounts 236:5
`
`analog 105:4
`
`analogs
`105:8
`
`102:5
`
`analyzed 31:6
`33:22 36:21
`
`153:20154:16
`
`155:18159221
`
`167:9,14,15 172:5
`1762719823
`
`800-642-1099
`
`A Veritext Company
`
`wwyeritextcom
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`
`Page 257 of 297
`
`
`
`
`
` [arterial - back] Page 5
`
`arterial 36:12
`
`100:21 102:18
`
`245:5,11 246:12
`
`averages
`
`150:6
`
`105:17114:5,14
`
`108:7,22111:21
`
`247:7,10,16
`
`159:7
`
`114:20,22 115:4,7
`
`227:21 230:10
`
`attempt
`
`135:7
`
`aware 40:24 41:7
`
`123:13,24,25
`
`126:25 128:9
`
`130:3134:19
`
`aspire 80:5
`
`asserted 226:14
`
`assessment 84:12
`
`135:18137:10
`
`[44:20
`
`139:7 157:22
`158:4,10 159:22
`177:9,15 232:20
`article 4:14161:6
`
`161:14172:13
`
`assigned 235:5
`assignee 206:13
`231:21
`
`assignees 220:25
`assist 21:1242:19
`
`193:19
`
`assistance 245:18
`
`articles 10:2125;4
`
`assistant 24:10
`
`25:7
`articulated 85:16
`
`assisted 20:20
`24:18
`
`178:8
`arts 25:24
`
`asked 13:5 45:15
`87:17 90:17 94:20
`
`97:3,19 104:9
`108:4 113:19
`203:24 209:12
`213:12246:18
`asking 33:19
`69:14 90:12 96:7
`
`100:5,18 108:23
`
`113:23 134:18
`1399 143:9
`182:11215:12
`aspect 9:22 26:22
`5724,25 95:20
`aspects 26:24 31:6
`42:20 47:5,24
`78:20 80:23 84:20
`87:25 88:7,18
`89:7,1690:19,20
`90:24 91:2,5,8
`92:25 93:4,12,18
`93:22,24 94:3
`97:9 99:22 100:3
`
`associated 43:7
`115:11 121:2
`
`124:2,10 189:22
`192:3 193:11
`
`196:25 230:9
`assume 66:4 91:21
`91:21 122:17
`assuming 58:8
`212:17225:20
`239:10
`
`assumption
`
`225:25
`attached 68:4
`126:2 249:12
`252:11
`attachment 36:4
`37:7,22 38:3 71:3
`71:15 73 :2,5
`126:3 129:12
`134:8 135:13
`137:3141:12,18
`141:21,22 152:21
`attachments 38:5
`39:12,24 40:17:22
`41 :3 24121923
`
`
`
`152:3 155:20
`
`166:22
`
`attend 29:2
`
`attorney 32:3
`
`250:24 251:2
`252:13
`attributable 57:16
`
`58:12 76:18 86:22
`
`attributes 81:8
`
`128:6 203:4
`
`230:10
`
`austin 2:14
`author 190:23
`
`175 :24,25
`authors
`176:18190:25
`
`191:5
`availability
`
`201 :22 202:9,11
`202:22,24 203:6
`available 53:9
`56:8,1061:10
`155:3,7,12,17,19
`158:2160:11,15
`
`160121 16112
`
`166:18 170:11
`177:9 188:18,20
`188:23196:13,14
`197:8 198:19,20
`198:21 199:21,24
`200:3 203:8,11
`206:18 217:10
`218:20 227:8
`average 34:14,19
`35:2149:22
`156:20158:25
`159:16,18 161:6
`173:3 174:13,16
`
`
`
`49:14 50:7 52:23
`
`53:22,24 54:8
`
`59:12 61:8,18,24
`
`62:8,18 63:6
`
`103:4 109:24
`122:7 124:12
`133:17135:11,13
`
`140:2 155:3,7,l9
`
`157:25160:10,15
`
`166:18 169:23,25
`
`170:7176:20,24
`
`177:20,23 179:17
`188:15 196:6
`
`201:18 223:18,20
`231:4 244:12
`
`b
`
`,
`
`_
`
`_
`
`b 7.??? 333213
`126:3 129:0
`13124 13224
`134:8135:13
`136:21 137:3
`
`14l:12,22152:21
`-
`
`h32c6ltglgl7-205'25
`bachelorg 21:22
`25:192024
`back 34:6 7 43:8
`61:7 64:15 12
`75:23 1012’21
`1065 “2:10
`1 13:4 1 15:13
`116:7129:6 8
`131251477121?
`149:8 15523 ’
`1613 ”2:12
`18435195216
`2042] 214:8
`
`
`
`800-642-1099
`
`A Veritext Company
`
`wwveritextcom
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-O1622
`
`Page 258 of 297
`
`
`
`Page 6
`[back - bullet]
`
`240:6,7
`
`background 21:21
`25:18 52:22
`
`bad 146:7
`
`behalf 2:2,10 5:19
`5:22 18:22
`
`big 222223
`billion 36:25
`
`bobby 2:15 5:15
`38:7
`
`believe
`
`19:22
`
`152:15,25153:14
`
`22:14 24:12,24
`
`153:24 154:8,22
`
`ballpark 8:12,15
`20:7
`
`29:22 30:10,17
`35:24 37:8 44:9
`
`158:24159:10,11
`159:20 160:18
`
`bargaining
`10:16
`
`base
`
`172:21
`
`10:16
`
`44:14 49:8 54:5
`
`billions
`
`150:20
`
`226:12 228:4
`
`54:19,25 62:4
`67:8 70:20 94:9
`
`biochemical 138:5
`
`boston 40:19
`
`140:12
`
`bottom 244:23
`
`based 10:1019:10
`
`97:17 116224
`
`bit
`
`118:17
`
`brand 16:21
`
`body 108:9,12
`book 36:19 48:23
`
`49:10 55:13176:2
`
`220:11 224:20
`
`57:17 58:4,5 60:9
`63: 10 68:19 70:22
`
`147:16,21 148:5,7
`148:14 155:6
`
`70:24 72:16,]9
`74:3 76:16 79:23
`
`162:11170:3,13
`171:8177:3178:6
`
`80:14 82:21,25
`83:22 88:21 107:2
`
`180:20 186:2
`
`211:5 212:16
`
`107:3 114:4,4
`
`140:18,21,25
`
`142:3,12143:20
`143:24145:10
`
`215:10,25 217:6
`217:12 225:24
`
`241:12
`
`146:7 147:7
`
`benchmark 173:9
`
`162:12163:22
`
`block 210:8 221:4
`
`144:15
`
`221:7 226:15
`
`branded 32:21
`
`blockbuster
`
`151:3
`
`break 7:12,14
`
`blocked 210:4
`
`221:18,25 223:5
`225:2 226:20
`
`230:16,24 232:9
`238:10 239:14
`
`63:25 128:16,21
`152:19174:13
`
`204:12 239:23
`
`breakdown 43:16
`
`44:20 168:3
`
`blocking 8923,24
`93:20 204:8
`
`83:16 85:9 87:9
`
`87:16 88:10 99:7
`
`231:15 235:4
`
`blockers
`
`113:10
`
`breaths 78:3 81:23
`
`
`
`207:12,15,21
`
`208:2,4,7,15,20,25
`
`209:13,15,21,23
`
`210:13,21211:11
`
`211:13,15,16,23
`
`212:4 213:8,18,23
`
`214:3,13,14,18
`
`215:2,6 216:6
`
`219:8,10,17,19
`
`221:7 225:7,7,15
`
`226:3 227:18,25
`230:13 232:16
`
`238:18,22
`blocks 207217
`
`208:8,20 209:2
`blood 107:3
`
`bloodstream
`
`107:17
`
`board 1:3
`
`
`
`99:9,20,25 100:10
`
`101:12,19111:7
`
`brennan 20:16,]9
`21:15 24:18 25:9
`
`brennan's 21:20
`
`brief 232:18
`
`briefly 25:17
`66:17
`
`191:12
`
`bring
`195:7
`
`bringing 210:8
`221:10
`
`broader 70:12
`
`127:12 128:7
`
`222:24
`
`broadly 102:19
`brought 194:5
`221:25
`
`bullet
`
`129:19
`
`
`
`164:12175:6,11
`181:9 184:14
`
`173:13,19174:2,7
`174:20
`
`benchmarks
`
`186:25187:21
`
`155:25 156:6
`
`188:4 199:4
`
`benefit 74:14
`
`215:23 216:10,20
`
`217:3,7 220:7
`
`227:19,22
`
`101:4 122:2
`
`218:10
`
`benefits 43:7
`
`basically 121:7
`basis 79:3 80:16
`
`56:16 57:4,11
`
`73:20 74:18,23
`
`135:5,16143:6
`
`85:13,17,19 88:3,6
`
`157:16168:17,17
`169:21 170:24
`
`176:9 197:7
`
`200:11,24
`
`best 7:1619:12,18
`73:17102:2149:7
`
`bdelafield 2:16
`
`187:23 217:20
`
`becoming 145:17
`began 212:25
`
`beginning 64:9
`129:5 204:20
`
`218:8 224:22
`
`better 94:10123:6
`
`139:11
`
`beyond
`185:10
`
`175:3,4
`
`800-642-1099
`
`A Veritext Company
`
`wwyeritextcom
`
`David Feldman Worldwide
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES v. UNITED THERAPEUTICS, IPR2017-01622
`
`Page 259 of 297
`
`
`
`[burroughs - cited]
`Page 7
`
`135:2,3 136:14,14
`
`charts 247:7,8,12
`
`190:12 224:2,4
`
`230:9,10 231:6
`234:19 243:10
`
`certainly 27:5
`28:16 29:6 30:2
`
`69:22 167:13
`
`185:13,16196:21
`226:10 227:9
`
`certificate 250:2
`
`certified 1:17
`
`certify 249:10
`250:8
`
`cheating 8:23 9:8
`check 147:12
`
`188:17
`
`checked 71:9
`
`checking 188:22
`chemical 58:3
`
`chemist 215:17
`
`chemistry 215:19
`220:3
`
`chicago 1:19 2:6
`40:19 251:9
`
`choice
`
`135:21
`
`chose 162:20
`
`153:17,l7,25
`
`250:4,7
`
`burroughs 221 :4
`
`221:14,25 223:14
`C
`
`c 83:2190:10
`
`c.f.r. 64:20 65:13
`
`66:13
`
`calcium 113:9
`
`calculate 37:4
`
`70:23
`
`calculated 34:23
`
`35:24 69:10 158:3
`
`173:24
`
`calculation 72:8
`
`calculations 21:10
`
`21:14,]6,1837:23
`
`38:3172:15,22
`
`247:11,17,21
`calibration 10:15
`
`california 67:21
`
`call
`
`116:9 121:16
`
`122:15
`
`called 1:126:6
`
`11:6,813:12,25
`14:1015:1519:4
`
`20:22 22:13,16,18
`
`27:5,10,13 28:2
`31:7 33:10 35:16
`
`44:4,23 45:19
`59:15 67:1176:6
`
`83:20 90:19 94:4
`
`95:21 108:14
`
`110:24 122:5,5
`
`135:4,4143:7,21
`
`154:9157:16,16
`
`170:24,24 172:3,3
`183:9 186:5
`
`195:25196:17
`
`197:14 201:16
`
`204:9 239:21
`
`240:14,24 241:9
`
`241:11,13,21,22
`
`241:24,25 242:6
`
`cfr 64:25 65:17
`
`chronic
`
`129:20
`
`challenge 121:21
`224:13
`
`130:10,21 132:21
`cimas 2:13
`
`challenged 9:20
`10:19
`
`change 47:8109:6
`109:20110:12
`
`circulating 107:2
`
`circulatory 106:14
`108:3
`
`circumstance
`
`166:5 189210
`
`242:23,25 246:9
`
`187:18,25 199:19
`
`
`
`246:7,20 253:9,11
`
`253:13,15,17,19
`
`changed 175:14
`176:11 177:4
`
`changes 252:9
`253:5
`
`channel
`
`113:10
`
`176:3
`chapter
`characterization
`
`207:25
`
`characterize
`
`182:16
`
`chart 40:4,7,10
`98:8 156:21
`
`158:22 164:6
`
`241:17 242:2,5,9
`
`242:13,17 244:2
`
`246:12,25
`
`
`
`
`
`190:11 193:25
`
`197:13 226:25
`
`circumstances
`
`136:15143:18
`
`166:5 185:22
`
`201:12207:10
`
`citations 87:20
`
`180:6
`
`cite 25:4 43:6
`
`139:3 161:22
`
`163:7 172:9
`
`179:13,14,19,23
`
`191:21192:15,18
`247:3
`
`cited 40:13164:18
`
`175:25176:15
`
`179:21 180:4
`
`182:9 203:21
`
`220:19 242: 1 9
`
`cases 8:3,7,10,13
`8:1412:1214:20
`
`15:6 16:3,14,20
`
`l7:6,16,1718:22
`
`19:11,]5,19,21,25
`20:12 21:4 27:18
`
`27:23 29:9 30:5
`
`33:12 66:6 67:12
`
`103:17104:21
`
`161:17 168:16
`
`185:18 205:4,9,14
`205:20 228:8
`
`229:12 241:2
`
`ceo
`
`116:8
`
`certain 11:1712:4
`
`13:914:17 20:25
`
`49:2150:4 51:11
`
`86:9,11 87:25
`
`121:24126:18,21
`
`David Feldrnan Worldwide
`
`A Veritext Company
`
`wwyeritextcom
`
`10:967z3
`
`cancer 150:18,20
`
`capable 207:2,4
`
`capacity 129:22
`130:4
`
`capital 2:12
`189:21 192:2
`
`193:10
`
`capitalization
`183:8,12,16,22,23
`184:5
`
`156:5
`captures
`car 591246049
`
`60:12,l4,l6,17,24
`care 67:24148215
`
`career
`
`171:5
`
`carefully 252:3
`case 4:198:189:2
`
`9:17,2510:12
`
`800-642-1099
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2017-O1622
`
`Page 260 of 297
`
`
`
`[cites - common]
`Page 8
`
`
`cites 41:4
`
`civil 1:14
`
`class 30:6 105:19
`
`column 43:9
`
`115:10123z23
`
`135:12
`
`claim 31:20 43: 16
`
`43:19 44:16 46:7
`
`47:7 50:3 51:12
`
`124:7,16,24 125:5
`
`125:6,12126:7,11
`126:14 129:23
`
`combination
`
`162:22 164:16
`
`237:2 238:2
`
`63:15 69:7 70:8
`
`130:5 133:9
`
`combined 162:16
`
`82:11 83:13 84:9
`
`136:22 138:16
`
`come 17:9117:17
`
`classes
`
`124:13
`
`125:17 134:9
`
`118:13,18,21
`145:4
`
`137:21 139:17
`
`comes 27:19 30:7
`
`clear 38:19 52:7
`
`31:18 41:15 59:2
`
`69:18 77:22 81:18
`
`101:4121:17
`
`84:12,25 86:9,11
`
`87:2,25 101:10
`228:14 229:14
`
`235:25 236:8,9,25
`237:8
`
`claimed 42: 1 3,23
`43:7 49:16 52:20
`
`55:7,10 73:25
`81:9 82:4 84:6
`
`85:13,]6,19 87:23
`
`88:3,7,18 90:7
`
`91:6,13 94:6
`207:19 208:10
`
`209:5 230:2]
`
`153:25 154:6,9,17
`
`156:2 157:2,9,13
`157:18160:24
`
`164:24165:6,15
`
`166:2 169:6,17
`
`170118 171:6,17
`
`172:2 174:2,12,20
`
`180:14181:3,8,17
`183:24184:7
`
`185:19186:8,24
`
`189:7,18 190:9,20
`
`191:8,17,24
`
`192:13,17,23
`
`193:4,7,23 194:13
`
`194:22195:10,13
`
`195:15,22197:10
`
`197:16,21,25
`
`199:17200:8,10
`
`[52:12 226:13
`
`clearly 95:10
`
`clinical 31:5,23
`
`51:17 57:4,25
`63:23 68:13 73:19
`
`74:14,23 75:16
`
`76:22 81:4,11
`
`87:25 88:3,6
`
`144:16,17145:7
`218:10
`
`coming 145:16
`commencement
`
`250:10
`
`commercial 4:15
`
`12:16,21,25 13:15
`
`201:10202:12,20
`
`13:17,21,2514:6
`
`203:18,25 217:24
`
`14:15,2215:3,9,16
`15:1916:417:12
`
`218:21219:3,7
`
`
`
`
`
`17:14,19,2130:15
`
`33:5,9,15,23 34:16
`
`35:5,1147:4
`53:10 55:21 56:9
`
`5827,11 5919,24
`67:3 68:23 76:24
`
`77:21,22 78:22
`
`80:22 81:6,18
`
`82:6 83:21 84:3,5
`84:19 85:20 86:12
`
`86:21 87:3,10,23
`
`88:12,19 89:8
`
`90:2191:14,16
`
`92:12,16 93:4,13
`95:12 98:3111:22
`
`127:3 143:14
`
`145:25146:18
`
`147:7 148:8,16,25
`
`
`
`234:2,7,11 238:20
`commercialization
`
`189:23 192:4
`
`193:12208:21
`
`238:19
`
`commercialize
`
`225:13 239:8
`
`commercialized
`
`217:18
`
`commercializing
`225:10
`
`13:6
`
`commercially
`13:1014:11,14
`60:16 61:10
`
`173:10,13,19
`174:15177:8
`
`217:10218:20
`
`219:12
`
`common 51 :6
`
`claiming 215:14
`216:5 236:14
`
`claims 43:9,12,15
`
`9220,21 95:6
`97:9 98:14 100:23
`
`100:24101:3,17
`102:18 103:5
`
`44:3,6,10,13,19,21
`
`107:7108:18,22
`
`44:21,23 45:18,24
`
`130:5139:10,11
`
`46:5,8,9,12,16,18
`
`47:21,22 48:13
`
`49:3,2151:10
`
`54:14 55:17,20
`61:2162:15 63:11
`
`63:20 77:24 81:20
`
`84:20 86:4 87:8
`
`148:2,18 218:10
`224:8
`
`clinically 69:2
`81:3
`
`clinician 50:11
`
`96:14102:7,12,14
`138:15
`
`90:14 95:13 98:3
`
`clinicians
`
`102:21
`
`227:6 235:24
`
`closer
`
`159:16
`
`236221 238:7
`
`collection 211:15
`
`clarify 33:18
`44:22 72:21 93:23
`
`collectively 43:15
`44:1 1,19 46:6
`
`101:23 169:4
`
`171:15
`
`college 25:21
`
`colleges 29:2
`
`152:16153:15,21
`
`165:16
`
`800-642-1099
`
`David Feldman Worldwide
`
`A Veritext Company
`
`ww.veritext.com
`
`UNITED THERAPEUTICS, EX. 2035
`WATSON LABORATORIES V. UNITED THERAPEUTICS, IPR2017-01622
`
`Page 261 of 297
`
`
`
`Page 9
`[commonly - context]
`
`128:5 152:7
`
`58:23 63:2 92:19
`
`200:9,10 201:21
`
`competition 53:10
`53:16 112:15
`
`97:7111:18,19,24
`112:7 165:12
`
`202:15 214:18,25
`consideration 14:6
`
`113:14116:2,14
`
`121:5,6,12,17
`
`128:3,8140:8
`
`145:11,l3,21
`185:11
`
`166:4 169:19
`
`170:23 184:11
`
`186:21 188:2
`
`229:19,25
`conclusions 41:20
`
`97:69 141:24
`
`167:2 168:5,8,14
`
`168:18,24 169:3
`
`171:2 172:4,6
`181:8 186:14
`
`199:4 200:5
`
`competitive
`145:22
`
`199:8
`competitor
`competitors 70:13